Accuray Incorporated, a radiation oncology company, has announced a long-term collaboration with Lausanne University Hospital, Switzerland covering the CyberKnife and TomoTherapy Systems. The alliance is based on a mutual commitment to ongoing research in radiation oncology and the development of innovative treatments that improve the quality of life for cancer patients.

At Lausanne University Hospital, patients will now have access to the newest CyberKnife and TomoTherapy Systems on the market. Healthcare professionals may also gain exposure to both systems through peer-to-peer training and education at the hospital. In addition, the two respected organisations intend to collaborate on clinical development and ongoing product innovations, benefiting both healthcare professionals and their patients.

"Accuray continuously strives to provide clinicians and their patients with radiation treatment options that deliver superior tumor control and minimal side effects," said Lionel Hadjadjeba, SVP International Business & GM Accuray International. "The collaboration with Lausanne University Hospital will enable us to benefit from a group of extremely experienced and skilled clinicians and physicians, and accelerate clinical and product development opportunities that may enhance quality of care."

Lausanne University Hospital is a renowned academic hospital featuring an advanced oncology department and a strong team of clinicians and medical physicists lead by Prof. Pierre-Francois Leyvraz, General Manager, Lausanne University Hospital, Lausanne, Switzerland. Its technical platform is equipped with, among others, the TomoTherapy H Series recently upgraded with VoLO and TomoEDGE, and the CyberKnife M6 System. The hospital is viewed as a leader in medical care, research and training within the European community.

"We view Accuray as a 'partner of choice' and believe our collaboration will further our mission to pioneer medical advances in the field of radiation oncology that are recognized by clinicians around the world," said Prof. Pierre-Francois Leyvraz, General Manager, Lausanne University Hospital, Lausanne, Switzerland. "We're pleased with the agreement because it provides us with the opportunity to have a meaningful impact on the next generation of radiation oncology treatments."

The Accuray CyberKnife M6 Series and TomoTherapy H Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.